Live
- Archery World Cup: Deepika storms into individual semis; Compound Mixed Team in final
- Adopt zero-tolerance approach towards terrorism, India tells SCO member states
- Free haircut, 'mehendi' for women on offer as Maharashtra votes in Phase 2
- BJP president JP Nadda to visit Odisha on April 28
- Participation of women in workforce is a constitutional entitlement: SC
- Sabita, Secretary of the District Legal Services Authority, made a surprise visit to the sub-jail
- Superstars Yash, Rakshit Shetty cast their votes, underline importance of polling
- Hyderabad court denies bail to 3 police officers in phone tapping case
- Apollo Hospitals' unit to raise Rs 2,475 crore from PE firm Advent International
- More than 70 per cent voter turnout in Assam till 5 PM
Covaxin could be back-up for now, says AIIMS chief
Covaxin could be back-up for now, says AIIMS chief
Bharat Biotech's coronavirus vaccine, which is still undergoing clinical trial, is likely to be the ‘back-up’ vaccine in the coming days, Dr Randeep Guleria, the chief of Delhi's All-India Institute of Medical Sciences, said on Sunday as two vaccines got emergency approval from the country's drug regulator
New Delhi: Bharat Biotech's coronavirus vaccine, which is still undergoing clinical trial, is likely to be the 'back-up' vaccine in the coming days, Dr Randeep Guleria, the chief of Delhi's All-India Institute of Medical Sciences, said on Sunday as two vaccines got emergency approval from the country's drug regulator.
Politics has started over the approval to Covaxin, with several Opposition parties pointing out that the vaccine was approved without the full process.
Congress's Shashi Tharoor tweeted, "The Covaxin has not yet had Phase 3 trials. Approval was premature and could be dangerous. @drharshvardhan should please clarify. Its use should be avoided till full trials are over. India can start with the AstraZeneca vaccine in the meantime".
"I feel that in the coming days it is the Serum Institute vaccine that will be the main vaccine, Bharat Biotech only a backup for emergency use in case of reinfection," Dr Randeep Guleria said.
"By that time, they will get their dosage ready and by the time they will get the data which will be able to show that the phase 3 data is robust and they have enough events to show that it is efficacious and it is safe, we will be able to have that vaccine available. But the first few weeks, it will be the serum institute vaccine which will be rolled out. It has 50 million doses available," Dr Guleria said.
Covaxin, the clinical trial of which is being conducted in collaboration with the Indian Council of Medical Research, has completed only its I and II phase trials.
